{"id":"W2266546919","doi":"10.1212/wnl.80.7_supplement.p07.120","title":"Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120)","year":2013,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Alemtuzumab; Expanded Disability Status Scale; Multiple sclerosis; Internal medicine; Clinical endpoint; Relapsing remitting; Interferon beta; Interferon beta-1a; Physical therapy; Randomized controlled trial; Immunology; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002735354,0.0008882052,0.002307164,0.0005989291,0.000268584,0.0007738596,0.0005838244,0.001077239,0.001980598],"category_scores_gemma":[0.003404963,0.0002481522,0.002644648,0.0005461338,0.0006377863,0.0007185158,0.0004755686,0.001527721,0.0003146161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000560238,"about_ca_system_score_gemma":0.0006746986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001175379,"about_ca_topic_score_gemma":0.001942226,"domain_scores_codex":[0.9982843,0.001139751,0.0001413905,0.0001330136,0.0001155552,0.0001860074],"domain_scores_gemma":[0.9983437,0.000745724,0.0004224365,0.0000888333,0.00008291031,0.0003162663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9427896,0.005642658,0.009169833,0.0005274364,0.002865733,0.00005302194,0.00007392801,0.0004738593,0.001688911,0.00006334999,0.0004917961,0.03615991],"study_design_scores_gemma":[0.4624082,0.4577852,0.06867347,0.0002423162,0.006056076,0.0001699595,0.0001022644,0.001041046,0.002481272,0.0002202511,0.0007842655,0.00003574252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941347,0.004251891,0.00005539475,0.0001749943,0.0001068561,0.0001475597,0.0002797708,0.00001202751,0.0008367577],"genre_scores_gemma":[0.9975463,0.001201039,0.0001797721,0.0001538933,0.0002160584,0.0001228047,0.0002955913,0.000003513013,0.0002810909],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002735354,"threshold_uncertainty_score":0.01446605,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04125256935688094,"score_gpt":0.277700388755741,"score_spread":0.2364478193988601,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}